Coronavirus – A 3rd dose for RNA vaccines under study at Swissmedic

Coronavirus – A 3rd dose for RNA vaccines under study at Swissmedic
Coronavirus – A 3rd dose for RNA vaccines under study at Swissmedic

PostedSeptember 16, 2021, 5:18 PM

Manufacturers Pfizer and Moderna last week filed dosage modification requests for their anti-Covid vaccine with the Swiss regulator.

Currently, Swissmedic recommends two doses for the Pfizer and Moderna vaccines.

AFP

Swissmedic is currently studying the possible recommendation of a 3rd dose for the vaccines from Pfizer and Moderna, the supervisory body reports in a press release on Thursday. The two manufacturers filed last week requests to this effect.

Change requests

At present, “Moderna (Spikevax) and Pfizer / BioNTech (Comirnaty®) Covid-19 vaccines are authorized in Switzerland for persons aged 12 and over, and are both administered at a rate of two doses, ”writes Swissmedic. Modern and Pfizer having both requested the modification of the current dosage recommendations of their vaccines, the Swiss regulator is therefore studying the clinical data received on this subject.

Safety and efficiency

In particular, Swissmedic will have to assess the safety and efficacy of these third doses (boosters or “boosters”), and decide whether the information at its disposal is sufficient to broaden the recommendation. The institute recalls that it “analyzes as a priority all requests related to the Covid-19 pandemic without making any compromise on the examination of the content.”

No date has yet been set by Swissmedic regarding its decision, which also depends on the results of clinical trials.

(lgb/comm.)

Source

Coronavirus #3rd dose RNA vaccines study Swissmedic

 
For Latest Updates Follow us on Google News
 

PREV Covid figures on the rise: “We underestimate the danger of the virus,” says Elio Di Rupo
NEXT of Lyonnais regenerate lost neurons